Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the sudden changes in life occurring everywhere. We are ensconced in our usual corner of the Pharmalot campus, where the short person is learning online and the street noise that usually wafts in through the windows has evaporated. Such is the new reality. Nonetheless, there is much to be done. So on that note, here are a few tidbits to help you focus. Hope your day goes well and that you remain healthy.

In response to a dire shortage of tests for detecting the novel coronavirus, the FDA gave states new powers to authorize labs to develop their own diagnostics, and it also approved new tests that will be distributed by LabCorp (LH) and Hologic (HOLX), STAT says. The agency will allow states to take responsibility for tests developed and used by laboratories within their borders, a step that is similar to what the FDA last week granted to the New York State Department of Health. The labs will not have to pursue an emergency clearance that is normally required.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.